Characterization With KRAS Mutant Is a Critical Determinant in Immunotherapy and Other Multiple Therapies for Non-Small Cell Lung Cancer

Characterization With KRAS Mutant Is a Critical Determinant in Immunotherapy and Other Multiple Therapies for Non-Small Cell Lung Cancer

Non-small cell lung cancer (NSCLC) is a frequent type of cancer, which is mainly characterized clinically by high aggressiveness and high mortality. KRAS oncoprotein is the most common molecular protein detected in NSCLC, accounting for 25% of all oncogenic mutations. Constitutive activation of the...

Full description

Bibliographic Details
Main Authors: Mo Shen, Rongbin Qi, Justin Ren, Dongqing Lv, Haihua Yang
Format: Article
Language:English
Published: Frontiers Media S.A. 2022-01-01
Series:Frontiers in Oncology
Subjects:
KRAS
NSCLC
chemotherapy
immunotherapy
targeted therapy
Online Access:https://www.frontiersin.org/articles/10.3389/fonc.2021.780655/full

Internet

https://www.frontiersin.org/articles/10.3389/fonc.2021.780655/full

Similar Items